메뉴 건너뛰기




Volumn 55, Issue , 2015, Pages 125-136

Neovascular age-related macular degeneration

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; HYBRID PROTEIN; RANIBIZUMAB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

EID: 84947235407     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000438969     Document Type: Article
Times cited : (63)

References (65)
  • 1
    • 11144354339 scopus 로고    scopus 로고
    • Prevalence of age-related macular degeneration in the United States
    • Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122:564-572.
    • (2004) Arch Ophthalmol , vol.122 , pp. 564-572
    • Friedman, D.S.1    O'Colmain, B.J.2    Munoz, B.3
  • 2
    • 0021752680 scopus 로고
    • Age-related macular degeneration and blindness due to neovascular maculopathy
    • Ferris FL, Fine SL, Hyman L: Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102:1640-1642.
    • (1984) Arch Ophthalmol , vol.102 , pp. 1640-1642
    • Ferris, F.L.1    Fine, S.L.2    Hyman, L.3
  • 3
    • 0026681119 scopus 로고
    • Prevalence of age-related maculopathy the Beaver Dam Eye Study
    • Klein R, Klein BE, Linton KL: Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99:933-943.
    • (1992) Ophthalmology , vol.99 , pp. 933-943
    • Klein, R.1    Klein, B.E.2    Linton, K.L.3
  • 4
    • 0034102998 scopus 로고    scopus 로고
    • Hypertension, cardiovascular disease, and age-related macular degeneration Age-Related Macular Degeneration Risk Factors Study Group
    • Hyman L, Schachat AP, He Q, et al. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 2000; 118:351-358.
    • (2000) Arch Ophthalmol , vol.118 , pp. 351-358
    • Hyman, L.1    Schachat, A.P.2    He, Q.3
  • 5
    • 34249680358 scopus 로고    scopus 로고
    • Cardiovascular risk factors and the long-Derm incidence of age-related macular degeneration: The Blue Mountains Eye Study
    • Tan JS, Mitchell P, Smith W, et al. Cardiovascular risk factors and the long-Derm incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2007; 114:1143-1150.
    • (2007) Ophthalmology , vol.114 , pp. 1143-1150
    • Tan, J.S.1    Mitchell, P.2    Smith, W.3
  • 6
    • 16244368037 scopus 로고    scopus 로고
    • Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report No 19
    • Clemons TE, Milton RC, Klein R, et al. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS). AREDS report No. 19. Ophthalmology 2005; 112:533-539.
    • (2005) Ophthalmology , vol.112 , pp. 533-539
    • Clemons, T.E.1    Milton, R.C.2    Klein, R.3
  • 7
    • 20244380171 scopus 로고    scopus 로고
    • Complement factor H polymorphism in age-related macular degeneration
    • Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308:385-389.
    • (2005) Science , vol.308 , pp. 385-389
    • Klein, R.J.1    Zeiss, C.2    Chew, E.Y.3
  • 8
    • 84887210076 scopus 로고    scopus 로고
    • CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration
    • Awh CC, Lane AM, Hawken S, et al. CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration. Ophthalmology 2013; 120:2317-2323.
    • (2013) Ophthalmology , vol.120 , pp. 2317-2323
    • Awh, C.C.1    Lane, A.M.2    Hawken, S.3
  • 9
    • 0031873513 scopus 로고    scopus 로고
    • Age-related macular degeneration and risk factors for the development of choroidal neovascularization in the fellow eye
    • Pieramici DJ, Bressler SB: Age-related macular degeneration and risk factors for the development of choroidal neovascularization in the fellow eye. Curr Opin Ophthalmol 1998; 9:38-46.
    • (1998) Curr Opin Ophthalmol , vol.9 , pp. 38-46
    • Pieramici, D.J.1    Bressler, S.B.2
  • 10
    • 8544234955 scopus 로고    scopus 로고
    • Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration Macular Photocoagulation Study Group
    • Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration Macular Photocoagulation Study Group. Arch Ophthalmol 1997 115 741-747.
    • (1997) Arch Ophthalmol , vol.115 , pp. 741-747
  • 11
    • 33746373850 scopus 로고    scopus 로고
    • Age-related macular degeneration (AMD): Pathogenesis and therapy
    • Nowak JZ: Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006; 58:353-363.
    • (2006) Pharmacol Rep , vol.58 , pp. 353-363
    • Nowak, J.Z.1
  • 12
    • 0142122287 scopus 로고    scopus 로고
    • Retinal and choroidal angiogenesis: Pathophysiology and strategies for inhibition
    • Das A, McGuire PG: Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003; 22:721-748.
    • (2003) Prog Retin Eye Res , vol.22 , pp. 721-748
    • Das, A.1    McGuire, P.G.2
  • 13
    • 84861722422 scopus 로고    scopus 로고
    • What are the half-lives of ranibizumab and aflibercept (VEGF Trap-Eye) in human eyes? Calculations with a mathematical model
    • Stewart MW: What are the half-lives of ranibizumab and aflibercept (VEGF Trap-Eye) in human eyes? Calculations with a mathematical model. Eye Reports 2011; 1:e5.
    • (2011) Eye Reports , vol.1 , pp. e5
    • Stewart, M.W.1
  • 14
    • 0029831672 scopus 로고    scopus 로고
    • Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor
    • Kvanta A, Algvere PV, Berglin L, et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37:1929-1934.
    • (1996) Invest Ophthalmol Vis Sci , vol.37 , pp. 1929-1934
    • Kvanta, A.1    Algvere, P.V.2    Berglin, L.3
  • 15
    • 0029935043 scopus 로고    scopus 로고
    • Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation
    • Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996; 80:363-366.
    • (1996) Br J Ophthalmol , vol.80 , pp. 363-366
    • Wells, J.A.1    Murthy, R.2    Chibber, R.3
  • 16
    • 0030952289 scopus 로고    scopus 로고
    • Mechanisms of angiogenesis
    • Risau W: Mechanisms of angiogenesis. Nature 1997; 386:671-674.
    • (1997) Nature , vol.386 , pp. 671-674
    • Risau, W.1
  • 17
    • 0344541763 scopus 로고    scopus 로고
    • Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes
    • Grossniklaus HE, Gass JD: Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 1998; 126:59-69.
    • (1998) Am J Ophthalmol , vol.126 , pp. 59-69
    • Grossniklaus, H.E.1    Gass, J.D.2
  • 18
    • 33644873981 scopus 로고    scopus 로고
    • Neovascular age-related macular degeneration: Natural history and treatment outcomes
    • Pauleikhoff D: Neovascular age-related macular degeneration: natural history and treatment outcomes. Retina 2005; 25:1065-1084.
    • (2005) Retina , vol.25 , pp. 1065-1084
    • Pauleikhoff, D.1
  • 19
    • 0035009086 scopus 로고    scopus 로고
    • Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy Report 2
    • Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration.
    • Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol 2001; 131:541-560.
    • (2001) Am J Ophthalmol , vol.131 , pp. 541-560
  • 20
    • 0035124965 scopus 로고    scopus 로고
    • Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials-DAP report 2
    • Bressler NM: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-DAP report 2. Arch Ophthalmol 2001; 119:198-207.
    • (2001) Arch Ophthalmol , vol.119 , pp. 198-207
    • Bressler, N.M.1
  • 21
    • 37449010146 scopus 로고    scopus 로고
    • The natural history and prognosis of neovascular age-related macular degeneration: A systematic review of the literature and meta-Analysis
    • Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-Analysis. Ophthalmology 2008; 115:116-126.
    • (2008) Ophthalmology , vol.115 , pp. 116-126
    • Wong, T.1    Chakravarthy, U.2    Klein, R.3
  • 22
    • 0026409933 scopus 로고
    • Argon laser photocoagulation for neovascular maculopathy Five-year results from randomized clinical trials Macular Photocoagulation Study Group
    • Argon laser photocoagulation for neovascular maculopathy Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991 109 1109-1114.
    • (1991) Arch Ophthalmol , vol.109 , pp. 1109-1114
  • 23
    • 0028349664 scopus 로고
    • Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration Macular Photocoagulation Study Group
    • Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration Macular Photocoagulation Study Group. Arch Ophthalmol 1994 112 489-499.
    • (1994) Arch Ophthalmol , vol.112 , pp. 489-499
  • 24
    • 7444227954 scopus 로고    scopus 로고
    • Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Ophthalmic findings: SST report No 11
    • Hawkins BS, Bressler NM, Miskala PH, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report No. 11. Ophthalmology 2004; 111:1967-1980.
    • (2004) Ophthalmology , vol.111 , pp. 1967-1980
    • Hawkins, B.S.1    Bressler, N.M.2    Miskala, P.H.3
  • 25
    • 33747891752 scopus 로고    scopus 로고
    • Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration
    • Chakravarthy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113:1508.e1-1508.e25.
    • (2006) Ophthalmology , vol.113 , pp. 1508e1-1508e25
    • Chakravarthy, U.1    Adamis, A.P.2    Cunningham, E.T.3
  • 26
    • 11144239923 scopus 로고    scopus 로고
    • Pegaptanib for neovascular age-related macular degeneration
    • Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351:2805-2816.
    • (2004) N Engl J Med , vol.351 , pp. 2805-2816
    • Gragoudas, E.S.1    Adamis, A.P.2    Cunningham, E.T.3
  • 27
    • 33749445317 scopus 로고    scopus 로고
    • Ranibizumab for neovascular age-related macular degeneration
    • Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1419-1431.
    • (2006) N Engl J Med , vol.355 , pp. 1419-1431
    • Rosenfeld, P.J.1    Brown, D.M.2    Heier, J.S.3
  • 28
    • 33749451356 scopus 로고    scopus 로고
    • Ranibizumab versus verteporfin for neovascular age-related macular degeneration
    • Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355:1432-1444.
    • (2006) N Engl J Med , vol.355 , pp. 1432-1444
    • Brown, D.M.1    Kaiser, P.K.2    Michels, M.3
  • 29
    • 57949094834 scopus 로고    scopus 로고
    • Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
    • ANCHOR Study Group.
    • Brown DM, Michels M, Kaiser PK, et al. ANCHOR Study Group: Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116:57-65.
    • (2009) Ophthalmology , vol.116 , pp. 57-65
    • Brown, D.M.1    Michels, M.2    Kaiser, P.K.3
  • 30
    • 43049176776 scopus 로고    scopus 로고
    • Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): Year 2 results
    • Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145:862-874.
    • (2008) Am J Ophthalmol , vol.145 , pp. 862-874
    • Antoszyk, A.N.1    Tuomi, L.2    Chung, C.Y.3
  • 31
    • 34548721616 scopus 로고    scopus 로고
    • Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial results to the treatment of everyday patients
    • Brown DM, Regillo CD: Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007; 144:627-637.
    • (2007) Am J Ophthalmol , vol.144 , pp. 627-637
    • Brown, D.M.1    Regillo, C.D.2
  • 32
    • 33947403618 scopus 로고    scopus 로고
    • An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration
    • Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143:566-583.
    • (2007) Am J Ophthalmol , vol.143 , pp. 566-583
    • Fung, A.E.1    Lalwani, G.A.2    Rosenfeld, P.J.3
  • 33
    • 84877759606 scopus 로고    scopus 로고
    • Twelve-month efficacy and safety of 0.5 or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration
    • HARBOR Study Group.
    • Busbee BG, Ho AC, Brown DM, et al. HARBOR Study Group: Twelve-month efficacy and safety of 0.5 or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013; 120:1046-1056.
    • (2013) Ophthalmology , vol.120 , pp. 1046-1056
    • Busbee, B.G.1    Ho, A.C.2    Brown, D.M.3
  • 34
    • 84908469619 scopus 로고    scopus 로고
    • Systemic vascular safety of ranibizumab for age-related macular degeneration
    • Ueta T, Noda Y, Toyama T, et al Systemic vascular safety of ranibizumab for age-related macular degeneration. Ophthalmology 2014 121 2193-2203.
    • (2014) Ophthalmology , vol.121 , pp. 2193-2203
    • Ueta, T.1    Noda, Y.2    Toyama, T.3
  • 35
    • 20144372969 scopus 로고    scopus 로고
    • Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study
    • Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112:1035-1047.
    • (2005) Ophthalmology , vol.112 , pp. 1035-1047
    • Michels, S.1    Rosenfeld, P.J.2    Puliafito, C.A.3
  • 36
    • 33745091547 scopus 로고    scopus 로고
    • Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration
    • Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26:383-390.
    • (2006) Retina , vol.26 , pp. 383-390
    • Spaide, R.F.1    Laud, K.2    Fine, H.F.3
  • 37
    • 36549039554 scopus 로고    scopus 로고
    • Pharmacokinetics of intravitreal ranibizumab (Lucentis)
    • Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114:2179-2182.
    • (2007) Ophthalmology , vol.114 , pp. 2179-2182
    • Bakri, S.J.1    Snyder, M.R.2    Reid, J.M.3
  • 39
    • 79956218863 scopus 로고    scopus 로고
    • Ranibizumab and bevacizumab for neovascular age-related macular degeneration
    • CATT Research Group.
    • Martin DF, Maguire MG, Ying GS, et al. CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364:1897-908.
    • (2011) N Engl J Med , vol.364 , pp. 1897-1908
    • Martin, D.F.1    Maguire, M.G.2    Ying, G.S.3
  • 40
    • 84863320414 scopus 로고    scopus 로고
    • Ranibizumab and bevacizumab for neovascular age-related macular degeneration: Two-year results
    • Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group
    • Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119:1388-1398.
    • (2012) Ophthalmology , vol.119 , pp. 1388-1398
    • Martin, D.F.1    Maguire, M.G.2    Fine, S.L.3
  • 41
    • 84863327423 scopus 로고    scopus 로고
    • Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
    • IVAN Study Investigators
    • IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119:1399-1411.
    • (2012) Ophthalmology , vol.119 , pp. 1399-1411
    • Chakravarthy, U.1    Harding, S.P.2    Rogers, C.A.3
  • 42
    • 84886430519 scopus 로고    scopus 로고
    • Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2 year findings of the IVAN randomized controlled trial
    • IVAN Study Investigators.
    • Chakravarthy U, Harding SP, Rogers CA, et al. IVAN Study Investigators: Alternative treatments to inhibit VEGF in age-related choroidal neovascularization: 2 year findings of the IVAN randomized controlled trial. Lancet 2013; 382:1258-1267.
    • (2013) Lancet , vol.382 , pp. 1258-1267
    • Chakravarthy, U.1    Harding, S.P.2    Rogers, C.A.3
  • 43
    • 84887176870 scopus 로고    scopus 로고
    • Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL Noninferiority Randomized Trial
    • GEFAL Study Group.
    • Kodjikian L, Souied EH, Minoun G, et al. GEFAL Study Group: Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL Noninferiority Randomized Trial. Ophthalmology 2013; 120:2300-2309.
    • (2013) Ophthalmology , vol.120 , pp. 2300-2309
    • Kodjikian, L.1    Souied, E.H.2    Minoun, G.3
  • 44
    • 84874654113 scopus 로고    scopus 로고
    • A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration
    • MANTA Research Group.
    • Krebs I, Schmetterer L, Boltz A, et al. MANTA Research Group: A randomized double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013; 97:266-271.
    • (2013) Br J Ophthalmol , vol.97 , pp. 266-271
    • Krebs, I.1    Schmetterer, L.2    Boltz, A.3
  • 45
    • 84920748073 scopus 로고    scopus 로고
    • Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-And-extend protocol
    • Berg K, Pederson TR, Sandvik L, et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-And-extend protocol. Ophthalmology 2015; 122:146-152.
    • (2015) Ophthalmology , vol.122 , pp. 146-152
    • Berg, K.1    Pederson, T.R.2    Sandvik, L.3
  • 46
    • 0037143764 scopus 로고    scopus 로고
    • VEGF-Drap: A VEGF blocker with potent antitumor effects
    • Holash J, Davis S, Papadopoulos N, et al. VEGF-Drap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002; 99:11393-11398.
    • (2002) Proc Natl Acad Sci USA , vol.99 , pp. 11393-11398
    • Holash, J.1    Davis, S.2    Papadopoulos, N.3
  • 47
    • 84865129521 scopus 로고    scopus 로고
    • Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
    • Papadopoulos N, Martin J, Run Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15:171-185.
    • (2012) Angiogenesis , vol.15 , pp. 171-185
    • Papadopoulos, N.1    Martin, J.2    Run, Q.3
  • 50
    • 84891631034 scopus 로고    scopus 로고
    • Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of VIEW studies
    • Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of VIEW studies. Ophthalmology 2014; 121:193-201.
    • (2014) Ophthalmology , vol.121 , pp. 193-201
    • Schmidt-Erfurth, U.1    Kaiser, P.K.2    Korobelnik, J.F.3
  • 52
    • 79955085045 scopus 로고    scopus 로고
    • Pharmacotherapy for neovascular age-related macular degeneration: An analysis of the 100% of 2008 Medicare fee-for-service part B claims file
    • Brechner, RJ, Rosenfeld PJ, Babish JD, et al. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% of 2008 Medicare fee-for-service part B claims file. Am J Ophthalmol 2011; 151:887-895.
    • (2011) Am J Ophthalmol , vol.151 , pp. 887-895
    • Brechner, R.J.1    Rosenfeld, P.J.2    Babish, J.D.3
  • 54
    • 84860450956 scopus 로고    scopus 로고
    • Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of DENALI study
    • Kaiser PK, Boyer DS, Cruess AF, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of DENALI study. Ophthalmology 2012; 119:1001-1010.
    • (2012) Ophthalmology , vol.119 , pp. 1001-1010
    • Kaiser, P.K.1    Boyer, D.S.2    Cruess, A.F.3
  • 55
    • 84860452217 scopus 로고    scopus 로고
    • Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of MONT BLANC study
    • Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of MONT BLANC study. Ophthalmology 2012; 119:992-1000.
    • (2012) Ophthalmology , vol.119 , pp. 992-1000
    • Larsen, M.1    Schmidt-Erfurth, U.2    Lanzetta, P.3
  • 57
    • 0024566535 scopus 로고
    • A light microscopic and autoradiographic study of non-irridiated and irradiated ocular wounds
    • Chakravarthy U, Gardinder TA, Archer DB, et al. A light microscopic and autoradiographic study of non-irridiated and irradiated ocular wounds. Curr Eye Res 1989; 8:337-348.
    • (1989) Curr Eye Res , vol.8 , pp. 337-348
    • Chakravarthy, U.1    Gardinder, T.A.2    Archer, D.B.3
  • 58
    • 61749100479 scopus 로고    scopus 로고
    • Twelve-month short-Derm safety and visual-Acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration
    • Avila MP, Farah ME, Santos A, Duprat JP, et al. Twelve-month short-Derm safety and visual-Acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration. Br J Ophthalmol 2009; 93:305-309.
    • (2009) Br J Ophthalmol , vol.93 , pp. 305-309
    • Avila, M.P.1    Farah, M.E.2    Santos, A.3    Duprat, J.P.4
  • 59
    • 84873316131 scopus 로고    scopus 로고
    • Epimacular brachytherapy for neovascular age-related macular degeneration: A randomized, controlled trial (CABERNET)
    • Dugel PU, Bebchuk JD, Nau J, et al. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET). Ophthalmology 2013; 120:317-327.
    • (2013) Ophthalmology , vol.120 , pp. 317-327
    • Dugel, P.U.1    Bebchuk, J.D.2    Nau, J.3
  • 62
    • 84947293579 scopus 로고    scopus 로고
    • Dugel PU. American Academy of Ophthalmology Annual Meeting, Chicago, November 10
    • Dugel PU: Anti-platelet-derived growth factor: where do we stand? American Academy of Ophthalmology Annual Meeting, Chicago, November 10, 2012.
    • (2012) Anti-platelet-derived Growth Factor: Where Do We Stand?
  • 63
    • 77953530014 scopus 로고    scopus 로고
    • Combined inhibition of platelet-derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD)-results of a phase 1 study
    • Ophthotech Anti-PDGF in AMD Study Group E-Abstract 1260
    • Boyer DS; Ophthotech Anti-PDGF in AMD Study Group: Combined inhibition of platelet-derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD)-results of a phase 1 study. Invest Ophthalmol Vis Sci 2009; 50:E-Abstract 1260.
    • (2009) Invest Ophthalmol Vis Sci , vol.50
    • Boyer, D.S.1
  • 64
    • 0025837828 scopus 로고
    • Laser photocoagulation of subfoveal neovascular lesion in age-related macular degeneration: Results of a randomized clinical trial
    • Macular Photocoagulation Study Group.
    • Macular Photocoagulation Study Group: Laser photocoagulation of subfoveal neovascular lesion in age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 1991; 109:1220-1231.
    • (1991) Arch Ophthalmol , vol.109 , pp. 1220-1231
  • 65
    • 1942525885 scopus 로고    scopus 로고
    • Occult choroidal neovascularization Influence on visual outcome in patients with age-related macular degeneration
    • Macular Photocoagulation Study Group.
    • Macular Photocoagulation Study Group: Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol 1996; 114:400-412.
    • (1996) Arch Ophthalmol , vol.114 , pp. 400-412


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.